$TPST News

Tempest Therapeutics Files Prospectus For Offering 2.427M Common Shares On Behalf Of Selling Shareholders

Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors

Tempest Therapeutics Nicholas Maestas Resigns As CFO Effective June 5, 2026; Appoints Justin Trojanowski As Principal Financial Officer Effective June 5, 2026

Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds

Tempest Reports First Quarter 2026 Financial Results and Provides Business Update

Tempest Therapeutics Q1 Adj. EPS $(0.50) Misses $(0.28) Estimate

Tempest Presents Clinical Update at ISCT 2026 Annual Meeting

Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting

Tempest Therapeutics To Present Most Recent Clinical Data From Lead Dual-Targeting Chimeric Antigen Receptor T-Cell Therapy Product Candidate, TPST-2003, At ISCT Scientific Annual Meeting

Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T

Tempest Therapeutics Reaches Milestone In TPST-2003 Manufacturing Process

Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts

Tempest Reports Year End 2025 Financial Results and Provides Business Update

Tempest Therapeutics Q4 EPS $(0.62) Beats $(3.52) Estimate

Tempest Therapeutics Announces Up To $6 Million Private Placement

Tempest Therapeutics Announces Up To $6M Private Placement; Warrants Will Have Exercise Price Of $2.16/Share

Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026

Tempest Therapeutics Selects Cincinnati Children's AGCTC As Lead Contract Development And Manufacturing Partner To Conduct Formal Technology Transfer Of TPST-2003 For Treatment Of rrMM

Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026

Tempest Therapeutics Announces Clinical Data From Ongoing REDEEM-1 Phase 1/2a Trial Evaluating TPST-2003, CD19/BCMA Dual-Targeting CAR-T Therapy